Research and Markets (http://www.researchandmarkets.com/research/c4e583/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Mexico" report to their offering.
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
In June 2009, Mexico finally approved the modification of the General Health Law that will allow the sale and production of biologic and biosimilar medicines for the treatment of chronic diseases. Article 222 Bis defines and regulates biologic and biosimilar medicines, including the requirements to register and market these medicines. The new regulation represents sizeable opportunities for both local and foreign producers. Local producers such as Probiomed, Silanes and Landsteiner Scientific already produce biologic medicines in Mexico. Competition, however, is expected to arise from foreign producers. On a patient level, the new regulation provides product safety and availability.
Under a decree published on 5th August 2008, local manufacturing plant requirements are being phased out over a two- year period. Competition from foreign producers is going to increase, particularly from those which until now did not have the resources to establish manufacturing facilities in Mexico. Imports of antiretrovirals were released in August 2008. Imports of vitamins, homeopathic medicines, vaccines, sera, haemoderivatives and biologic hormones were released in February 2009. Producers of other biologics such as insulin and erythropoietin will also be able to export to Mexico from August 2009. The market will be fully open by the second half of 2010.